Colorectal Cancer Clinical Trials in Kansas City, MO

Colorectal Cancer Clinical Trials in Kansas City, MO

View the best 10 colorectal cancer medical studies in Kansas City, Missouri. Access promising new therapies by applying to a Kansas City-based Colorectal Cancer clinical trial.

Trials in Kansas City, Missouri

Here are the top 10 medical studies for colorectal cancer in Kansas City, Missouri

Image of Yale University Cancer Center LAO in New Haven, United States.

Temozolomide

Alkylating agents

Recruiting1 awardPhase 1 & 2
This trial tests a combination of two drugs, temozolomide and M1774, in patients with advanced cancer that has spread. Temozolomide damages cancer cell DNA, while M1774 blocks growth enzymes. The goal is to find a more effective treatment for these patients.
Image of UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, United States.

9-ING-41

GSK-3β inhibitor

Recruiting1 awardPhase 2
This trial is testing a new drug to see if it is safe and effective in treating cancer. The drug is designed to target a protein called GSK-3β, which is found in many different types of cancer cells.
Image of Moffitt Cancer Center in Tampa, United States.

KPT-8602

XPO1 inhibitor

Recruiting1 awardPhase 1 & 2
This trial will assess the safety, tolerability, and preliminary efficacy of KPT-8602, an oral XPO1 inhibitor, in patients with relapsed/refractory multiple myeloma, metastatic colorectal cancer, metastatic castration resistant prostate cancer, higher risk myelodysplastic syndrome, acute myeloid leukemia, and newly diagnosed intermediate/high-risk MDS.
Image of Northwestern University in Chicago, United States.

Atorvastatin Calcium

Statins

Recruiting0 awardsPhase 2
This trial studies atorvastatin, a cholesterol-lowering drug, in patients with ulcerative colitis who are at risk of colon cancer. The goal is to see if atorvastatin can reduce cancer risk by lowering cholesterol and affecting certain proteins and genes linked to cancer.
Image of City of Hope in Duarte, United States.

FPV-CV301 +3 More

Cancer Vaccine

Recruiting1 awardPhase 2
This trial is a multi-center Phase II randomized study of a new cancer treatment. 78 patients with liver metastases from colorectal cancer will be enrolled and randomly assigned to either the control arm or the experimental arm. The control arm will receive the standard of care, while the experimental arm will receive a new immunotherapy treatment in addition to the standard of care. The primary endpoint of the study is to assess the safety and efficacy of the new treatment.
Image of University of Kansas Cancer Center in Westwood, United States.

Cabozantinib +1 More

Tyrosine Kinase Inhibitor

Recruiting1 awardPhase 1 & 2
This trial is testing the safety of combining two drugs to treat gastroesophageal cancer and other gastrointestinal cancers. The goal is to find a more effective therapy for these patients.
Image of Moores Cancer Center, UCSD in La Jolla, United States.

Atezolizumab +1 More

Monoclonal Antibodies

Recruiting1 awardPhase 1 & 2
This trial is testing a new drug, DSP107, as a possible treatment for advanced solid tumors. The trial will assess the safety and efficacy of DSP107 given alone or in combination with atezolizumab.
Image of Sarcoma Oncology in Santa Monica, United States.

HBI-2438

Epigenetic Modulator

Recruiting1 awardPhase 1
This trial tests HBI-2438, an oral drug for patients with advanced solid tumors having the KRAS G12C mutation. The drug aims to stop cancer growth by blocking the faulty gene. Related drugs, Adagrasib and Sotorasib, have shown effectiveness in treating similar conditions.
Image of Cedars-Sinai Medical Center in Los Angeles, United States.

RGX-202-01 +1 More

Small Molecule Inhibitor

Recruiting1 awardPhase 1
This trial is testing a new drug, RGX-202-01, to see if it can shrink tumors in people with gastrointestinal cancer. The study will test different doses of the drug to see what is safe and effective. The study will also test the drug in combination with other drugs that are commonly used to treat gastrointestinal cancer.
Image of Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro in Jonesboro, United States.

Fluorouracil +4 More

Chemotherapy

Recruiting2 awardsPhase 3
This trial is testing a combination of chemotherapy drugs, bevacizumab, and atezolizumab to treat patients with metastatic colorectal cancer.

Phase 3 Trials

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.